Correction of presbyopia in hyperopia with a center-distance, paracentral-near technique using the Technolas 217z platform

PURPOSE: To analyze the results of hyperopic patients treated with a peripheral presbyLASIK algorithm for the correction of presbyopia. METHODS: The study included 44 eyes of 22 hyperopic patients treated with a peripheral presbyLASIK technique using a Technolas 217z excimer laser. Mean patient age was 56 years (range: 47 to 72 years), mean preoperative spherical equivalent refraction was +1.21 +/- 0.77 diopters (D) (range: +0.50 to +4.00 D), and mean spectacle near addition was +1.76 +/- 0.42 D (range: +1.00 to +2.75 D). The Peripheral Multifocal LASIK (PML) ablation pattern creates a multifocal corneal profile over a 6.5-mm diameter, performing the distance correction first in a 6-mm optical zone and then near correction in a 6.5-mm zone. Main outcome measures were uncorrected visual acuity (UCVA) and best spectacle-corrected visual acuity (BSCVA) for near and distance, spherical equivalent refraction, contrast sensitivity, and corneal aberrations. RESULTS: Six months postoperatively, mean binocular UCVA was 1.06 +/- 0.13 for distance and 0.84 +/- 0.14 for near. Mean postoperative spherical equivalent refraction was -0.42 D (range: -1.12 to +0.87 D). Two (4.5%) eyes lost 1 line of BSCVA for distance and near vision, and 20 (45%) eyes gained 1 line of distance BSCVA. Contrast sensitivity decreased for 3, 6, 12, and 18 cycles/degree. Corneal aberration analysis showed a slight increase in coma and decrease in spherical aberration. CONCLUSIONS: The peripheral presbyLASIK technique used in this study is a safe and efficient treatment that may improve functional near vision in presbyopic patients with low and moderate hyperopia (from +0.50 to +3.00 D).     

Comparison of optical zones in hyperopic laser in situ keratomileusis: 5.9 mm versus smaller optical zones

PURPOSE: To compare the results of hyperopic laser in situ keratomileusis (LASIK) with a 5.9 mm optical zone (OZ) with those with smaller zones (4.4 to 5.5 mm). SETTING: Instituto de la Visión, Buenos Aires, Argentina. METHODS: The results of LASIK with a 5.9 mm OZ (147 cases) were compared with those in a previously reported group treated with OZs of 4.4 to 5.5 mm (679 cases). In the 5.9 mm group, 31.3% (46 eyes) had low hyperopia, 46.9% (69 eyes) had moderate hyperopia, and 21.8% (32 eyes) had high hyperopia. In the smaller OZ group, follow-up was 1 month in 79.4% (539 eyes), 3 months in 75.5% (501 eyes), 6 months in 68.5% (465 eyes), and 1 year in 38.3% (260 eyes). The hyperopic population studied was divided into 3 subgroups based on the preoperative spherical equivalents of the manifest refraction: subgroup A, low hyperopia: < or = +2.0 diopters (D); subgroup B, moderate hyperopia: +2.0 to +3.0 D; and subgroup C, high hyperopia: > +3.0 D. The following parameters were measured postoperatively: uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), refraction (evolution and distribution), and visual acuity lines gained and lost. RESULTS:The preoperative mean spherical equivalents in the 5.9 mm OZ group were +1.47 +/- 0.41 (SD) (subgroup A); +2.98 +/- 0.41 (subgroup B); and +5.13 +/- 0.61 (subgroup C). In the smaller OZ group, they were +1.31 +/- 0.74, +2.56 +/- 0.28, and +5.28 +/- 0. 69, respectively. At 12 months, the distribution of eyes in the 5.9 mm OZ group with refractions within +/-1.0 D were as follows: subgroup A, 100%; subgroup B, 100%; and subgroup C, 94.2%. In the smaller OZ group, the distributions were 100%, 95.3%, and 71.4%. In the 5.9 mm and the smaller OZ groups, the UCVA was 20/40 or better in 92.0% and 81.8% of eyes, respectively, in subgroup A; 94.6% and 100%, respectively, in subgroup B; and 76.5% and 77.9%, respectively, in subgroup C. The percentage of eyes with 0 +/- 1 line of BCVA 12 months after the procedure was also determined in the 5.9 mm OZ group and compared with the percentages in the smaller OZ group. CONCLUSION: Results of hyperopic LASIK with a 5.9 mm OZ in eyes with low, moderate, and high hyperopia are more stable, predictable, and safe than those in eyes with OZs smaller than 5.9 mm.     

Hyperopic laser in situ keratomileusis with the Nidek EC-5000 excimer laser

OBJECTIVE: To evaluate the efficacy, safety, and predictability of hyperopic laser in situ keratomileusis (H-LASIK) using modified software. DESIGN: Retrospective, noncomparative case series. PARTICIPANTS: The first 72 consecutive eyes of 44 patients with up to +5.00 diopters (D) hyperopia. INTERVENTION: Hyperopic LASIK using the Automatic Corneal Shaper (ACS; Chiron Vision, Claremont, CA) and the Nidek EC-5000 excimer laser (Nidek, Tokyo, Japan). MAIN OUTCOME MEASURES: Uncorrected visual acuity, manifest spherical equivalent (MSE), best-corrected visual acuity (BCVA), and complications were studied. RESULTS: At 6 months, in the low hyperopia group (<3.00 D), mean MSE was +0.30 +/- 0.71 D, with 88.9% eyes within 1 D of emmetropia compared with +1.09 +/- 0.92 D and 51.8% within 1 D of emmetropia in the moderate hyperopia group (> or =3.00 D; P = 0.003). Uncorrected visual acuity was 20/40 or better in 43 of 45 eyes (95.6%) and in 21 of 27 (77.8%) eyes in the low and moderate hyperopia groups, respectively. Only one eye (1.4%) from the moderate hyperopia group lost two lines of BCVA. Eighteen eyes (25%) required retreatment to correct residual hyperopia, 9 eyes (20.0%) in the low hyperopia group and 9 eyes (33.3%) in the moderate hyperopia group. Retreatments resulted in an MSE of +0.02 +/- 0.45 D and +0.04 +/- 0.73 D in the low and moderate hyperopia groups, respectively. No flap-related complications were seen. CONCLUSIONS: Hyperopic LASIK with the ACS and the Nidek EC-5000 excimer laser using our modified software is a safe, effective, and predictable procedure for low hyperopia. Results are satisfactory up to moderate hyperopia. Significant regression can occur for low and moderate hyperopia. Retreatment can be performed safely and effectively to improve the visual and refractive results.     

Effect of varying the optical zone diameter on the results of hyperopic laser in situ keratomileusis.

PURPOSE: To compare the predictability and safety of laser in situ keratomileusis (LASIK) for low to moderate spherical hyperopia using different ablation zone diameters. DESIGN: Retrospective, nonrandomized, comparative trial. PARTICIPANTS: Forty-nine eyes that underwent hyperopic LASIK. INTERVENTION: Two surgeons (JMD, RKM) performed hyperopic LASIK using the VISX STAR S2 excimer laser (VISX, Inc., Sunnyvale, CA) and the Bausch & Lomb Hansatome microkeratome (Chiron Vision, Irvine, CA) using ablation zone diameters of 5 x 9 mm, 5.5 x 8.5 mm, or 6 x 9 mm (the first number represents the optical zone diameter and the second number represents the diameter of the outer border of the ablation zone). MAIN OUTCOME MEASURES: Refractive and visual outcomes at 3 to 6 months after surgery were analyzed. Groups were compared for deviations from targeted spherical equivalent, uncorrected visual acuity, and loss of best spectacle-corrected visual acuity (BSCVA). RESULTS: The mean intended hyperopic correction was +2.48 +/- 1.13 diopters (D; 0.63-5.50 D). There were 16 eyes in the 5 x 9-mm group, 15 eyes in the 5.5 x 8.5-mm group, and 18 eyes in the 6 x 9-mm group. On average, the 5 x 9-mm group achieved 97% of the programmed correction, the 5.5 x 8.5-mm group achieved 104%, and the 6 x 9-mm group achieved 112% of the programmed correction. The tendency toward overcorrection in the 6 x 9-mm group compared with the 5 x 9-mm group was statistically significant (P < 0.05). The incidence of one line loss of BSCVA was greatest in the 5 x 9-mm group (19%) and lowest in the 6 x 9-mm group (6%). These differences were not statistically significant. No eyes experienced a loss of two or more lines of BSCVA at last examination. CONCLUSIONS: Hyperopic LASIK using the VISX STAR is safe and effective using different ablation zone diameters. There appears to be an increased tendency toward overcorrection with progressively larger optical zone diameters.     

Laser in situ keratomileusis for hyperopia and hyperopic astigmatism with the Nidek EC-5000 Excimer laser.

PURPOSE: We evaluated the efficacy, predictability, stability, and safety of laser in situ keratomileusis (LASIK) for hyperopia and hyperopic astigmatism. METHODS: A retrospective study was performed for 92 eyes of 62 consecutive patients to evaluate uncorrected (UCVA) and best spectacle-corrected visual acuity (BSCVA) and manifest refraction before and 3 and 6 months after LASIK (Moria LSK-ONE microkeratome, Nidek EC-5000 excimer laser). Eyes were divided into groups: Group 1 (low hyperopia) for spherical correction of +1.00 to +3.00 D (22 eyes), Group 2 (low hyperopic astigmatism) for toric correction with spherical equivalent refraction of +1.00 to +3.00 D (18 eyes), Group 3 (moderate hyperopia) for spherical correction of +3.25 to +6.00 D (10 eyes), and Group 4 (moderate hyperopic astigmatism) for toric correction with spherical equivalent refraction between +3.25 and +6.00 D (18 eyes). RESULTS: At 3 and 6 months after LASIK, 68 eyes (73.9%) were available for follow-up examination. Percentage of eyes with a spherical equivalent refraction within +/-0.50 D of emmetropia for Group 1 was 54.5% (12 eyes); Group 2, 50% (9 eyes); Group 3, 40% (4 eyes), and Group 4, 38.8% (7 eyes). UCVA > or =20/20 in Group 1 was 14% and in Groups 2, 3, and 4, 0%. One eye (5.5%) lost two lines of BSCVA. CONCLUSION: LASIK with the Moria LSK-ONE microkeratome and the Nidek EC-5000 excimer laser reduced low and moderate hyperopia and was within +/-0.50 D of target outcome in approximately 50% of eyes. Undercorrection was evident in all groups. The procedure was safe.     

Laser-in-situ-Keratomileusis zur Korrektur von Hyperopie und hyperopem Astigmatismus mit Scanning-Spot-Excimer-Laser

PURPOSE: The purpose of this investigation was to evaluate the safety, efficacy, predictability, stability and complications of LASIK for the treatment of hyperopia and hyperopic astigmatism using a scanning spot excimer laser. PATIENTS AND METHODS: A total of 64 consecutive LASIK operations (37 patients, mean age 41 years, range 22-68 years) have been evaluated. The Hansatome microkeratome producing a superior hinge (flap diameter 9.5 mm) and a scanning spot excimer laser with an optical zone of 6.0 mm were used. Examinations were performed preoperatively, after 1 day, 7 days, 1 month, 4 and 12 months. RESULTS: One year after the primary procedure only 1 eye lost 2 or more lines of best-corrected visual acuity, 91% were within +/-1 line and 4 eyes gained 2 lines. Of these eyes 50 (86%) reached an uncorrected visual acuity of > or=0.5, 32 (55%) > or=0.8, 16 (28%) > or=1.0, 24 eyes (41%) needed a refractive correction of +/-0.5 D, 44 eyes (76%) of +/-1.0 D and 55 eyes (95%) of +/-2.0 D. The mean spherical equivalent after 1 year was +0.17+/-0.85 D. CONCLUSIONS: LASIK is suitable for the correction of hyperopia (up to a maximum of +5 D) and for hyperopic astigmatism (up to a maximum of -5 D). However, results were better in lower hyperopia (up to +3 D) than in the moderate hyperopia. The refractive results showed overall a good stability during the 12-month study period, but higher regression occurred in a few cases.     

Laser in situ keratomileusis for hyperopia and hyperopic and mixed astigmatism with LADARVision using 7 to 10-mm ablation diameters

PURPOSE: To evaluate the results of laser in situ keratomileusis (LASIK) performed to correct hyperopia, and hyperopic and mixed astigmatism using wider ablation diameters (optical zone diameter and overall ablation diameter) than those commonly used with the same and other lasers. METHODS: After flap creation using an Alcon SKBM microkeratome set for a 10-mm flap diameter, 53 eyes (33 patients) with a mean spheroequivalent attempted correction of +2.34 +/- 2.09 D underwent LASIK (Alcon LADARVision 4000) using a 7-mm optical zone diameter and a 3-mm transition zone for an overall 10-mm total ablation diameter. The nasal hinge was prevented from undesired ablation by the use of proprietary hinge protector software. Eyes were followed for 6 months after surgery. RESULTS: Six months after surgery, mean spheical equivalent refractive error was -0.22 +/- 0.41 D. There were 79.2% of eyes within +/- 0.50 D, and 98.1% within +/- 1.00 D of intended correction. Uncorrected visual acuity of 20/20 or better was achieved by 28 eyes (53%) and 20/40 or better by 50 eyes (94.3%). No meaningful visual complaints during nighttime hours, such as haloes or glare, were subjectively reported by patients. CONCLUSION: The use of larger ablation diameters in LASIK for hyperopia, and hyperopic and mixed astigmatism produced accurate results, early refractive stability, and good visual performance.     

Laser in situ keratomileusis for hyeropia and hyperopic astigmatism.

PURPOSE: To evaluate the efficacy, stability, and safety of laser in situ keratomileusis (LASIK) for hyperopia and hyperopic astigmatism using a prospective clinical trial. METHODS: LASIK was performed using the Automatic Corneal Shaper and the Keracor 117C excimer laser on 192 hyperopic eyes with astigmatism of less than 1.00 D (spherical group) and 164 hyperopic eyes with corneal astigmatism of 1.00 to 7.50 D (toric group). RESULTS: At 12 months after LASIK, 110 eyes were available for follow-up examination. In low spherical hyperopia (+1.00 to +3.00 D), 13 eyes (55%) were within +/-0.50 D of emmetropia and none lost 2 or more lines of spectacle-corrected visual acuity. In low toric hyperopia (+1.00 to +3.00 D), 14 eyes (61%) were within +/-0.50 D and none lost 2 or more lines of spectacle-corrected visual acuity. In moderate spherical hyperopia (+3.10 to +5.00 D) 9 eyes (44%) were within +/-0.50 D and none lost 2 or more lines of spectacle-corrected visual acuity and in moderate toric hyperopia (+3.10 to +5.00 D) 5 eyes (36%) were within +/-0.50 D and 2 eyes (14%) lost 2 or more lines of spectacle-corrected visual acuity. In high spherical hyperopia (+5.10 to +9.00 D), 6 eyes (38%) were within +/-0.50 D and 2 eyes (13%) lost 2 or more lines of spectacle-corrected visual acuity, and in high toric hyperopia (+5.10 to +9.50 D) 4 eyes (31%) were within +/-0.50 D and 2 eyes (15%) lost 2 or more lines of spectacle-corrected visual acuity. CONCLUSIONS: LASIK seems to be reasonably effective and safe in spherical hyperopia of +1.00 to +5.00 D but less effective for hyperopic astigmatism. For hyperopia greater than +5.00 D, loss of spectacle-corrected visual acuity occurred in a significant number of eyes and accuracy was sufficiently poor to advise against LASIK in these eyes.     

Photorefractive keratectomy using the meditec MEL 70 G-scan laser for hyperopia and hyperopic astigmatism

PURPOSE: To evaluate the results of photorefractive keratectomy (PRK) using Gaussian flying spot technology in the treatment of hyperopia and hyperopic astigmatism. METHODS: Two hundred eyes were evaluated with 12-month follow-up. An Asclepion-Meditec MEL 70 G-scan flying spot ArF excimer laser with a Gaussian scanner was used (6.0-mm treatment zone and 9.0-mm transition zone). Eyes were divided into four groups: Group 1 (spherical hyperopia up to +3.50 D and astigmatism less than 1.00 D, n=62); Group 2 (hyperopia up to +3.50 D and astigmatism of 1.00 D or more, n=44); Group 3 (hyperopia greater than +3.50 D and astigmatism less than 1.00 D, n=56); and Group 4 (hyperopia greater than +3.50 D and astigmatism of 1.00 D or more, n=38). RESULTS: In Group 1, 82.2% (51/62 eyes) were within +/-0.50 D of target refraction; 88.7% (55/62 eyes) had 20/20 or better uncorrected visual acuity; 1.6% (1/62 eye) lost two or more lines, 3.2% (2/62 eyes) gained two or more lines of spectacle-corrected visual acuity. In Group 2, 68.1% (30/44 eyes) were within +/-0.50 D; 77.2% (34/44 eyes) had 20/20 or better uncorrected visual acuity; 9.1% (4/44 eyes) lost two or more lines of spectacle-corrected visual acuity. In Group 3, 76.8% (43/56 eyes) were within +/-0.50 D; 78.6% (44/56 eyes) had 20/20 or better uncorrected visual acuity; 5.4% (3/56 eyes) lost two or more lines of spectacle-corrected visual acuity. In Group 4, 42% (16/38 eyes) were within +/-0.50 D; 60.5% (23/38 eyes) had 20/20 or better uncorrected visual acuity; 15.8% (6/38 eyes) lost two or more Snellen lines. CONCLUSION: PRK with the flying spot Meditec MEL 70 G-scan was most safe and effective for low hyperopia.     

Phakic refractive lens experience in Spain

PURPOSE: To evaluate the efficacy, predictability, and safety of a phakic refractive lens (PRL) for high myopia and hyperopia. SETTING: Instituto Oftalmológico Hoyos, Barcelona, Spain. METHODS: A PRL was implanted in 31 eyes (17 myopic, 14 hyperopic) with a mean preoperative spherical equivalent (SE) of -18.46 diopters (D) (range -11.85 to -26.00 D) for myopia and +7.77 D (range +5.25 to +11.00 D) for hyperopia. All eyes had a thorough ophthalmologic examination before and after surgery. The follow-up was at least 12 months. RESULTS: At 1 year, the mean postoperative SE in the myopic group was -0.22 D +/- 0.87 (SD) and 82% were within +/-1.00 D of the desired refraction. The mean postoperative SE in the hyperopic group was -0.38 +/- 0.82 D, and 79% were within +/-1.00 D. Snellen lines of visual acuity were gained in 65% of the myopic eyes (8 eyes gained 1 line, 3 eyes gained 2 lines), and no eye lost lines. In the hyperopic group, 1 eye gained 1 line of acuity and 1 eye lost 1 line. In the hyperopic group, complications included pupillary block in 2 eyes and pigment dispersion signs without intraocular hypertension in 1 eye. In the myopic group, 1 eye had a corticosteroid-induced intraocular pressure rise, 1 eye had a spot of anterior cortical lens opacity immediately after surgery that did not progress, and 3 eyes with the PRL model 100 had decentration that required replacement of the lens. Four patients (2 myopic, 2 hyperopic) reported night halos in both eyes. CONCLUSIONS: Results indicate that PRL implantation to correct high myopia and hyperopia is a relatively rapid, safe, predictable, and stable method that in many cases also improves the best corrected visual acuity. Complications such as visually significant progressive cataract and pigmentary glaucoma were not observed.     

Diode laser thermal keratoplasty to correct hyperopia

PURPOSE: We investigated long-term efficacy, predictability, stability, and safety of diode laser thermal keratoplasty (DTK) to correct hyperopia. METHODS: DTK was performed on 24 eyes (18 patients). Eight eyes with high hyperopia (mean +4.75 +/- 0.63 D; range +3.50 to +5.50 D) received 12 pairs of coagulation spots at 6-mm and 7-mm treatment zone diameters; eight eyes with low hyperopia (mean +2.25 +/- 0.40 D; range +1.50 to +2.75 D) received eight coagulation spots at 8 mm, and eight eyes with low hyperopia (mean +1.50 +/- 0.46 D; range +1.25 to +2.25 D) were treated to induce mild myopia (-1.50 D) in the non-dominant eye for monovision using eight pairs of spots at 7 and 8-mm diameters. Minimum follow-up was 18 months. RESULTS: Mean decrease in cycloplegic refraction at 18 months was 5.00 +/- 0.38 D in the high hyperopia group, 1.75 +/- 0.19 D in the low hyperopia group, and 3.25 +/- 0.27 D in the presbyopia group. Mean increase in uncorrected visual acuity (UCVA) at 18 months was 8.125 +/- 2.1 Snellen lines in the high hyperopia group, 6.625 +/- 0.744 lines for low hyperopia; decrease of 1.00 +/- 1.85 line occurred in the presbyopia group. Near UCVA in the presbyopia group improved by 3.875 +/- 0.83 Jaeger lines. Best spectacle-corrected visual acuity (BSCVA) was restored by 3 months in all eyes. CONCLUSION: DTK was an effective and fairly safe procedure, with reasonable predictability and stability. Nomograms for laser energy level, treatment zone diameter, and number of spots need improvement.     

Laser epithelial keratomileusis for the correction of hyperopia using a 7.0-mm optical zone with the Schwind ESIRIS laser

PURPOSE: To investigate the efficacy of laser epithelial keratomileusis (LASEK) for the correction of hyperopia using a 7.0-mm optical zone and a 9.0-mm total ablation zone diameter with the Schwind ESIRIS flying-spot laser. METHODS: Forty-seven patients (70 eyes) were treated with a mean preoperative spherical equivalent refraction of +2.32 diopters (D) (range: 0 to +5.00 D). All eyes underwent LASEK using 15% alcohol with a 20-second application. RESULTS: An intact epithelial flap was obtained in 66 (94%) eyes. In 70 eyes at 12 months, the mean spherical equivalent refraction was +0.09 D (range: -0.75 to +1.00 D) with all (100%) eyes within +/- 1.00 D of the intended correction and 60 (86%) eyes within +/- 0.50 D. In 40 eyes with 24-month follow-up, the refractive correction remained stable after 6 months. Hyperopic cylindrical corrections were attempted in 49 eyes (range: +0.25 to +5.00 D) with vector analysis demonstrating a mean 102% correction at 12 to 24 months. In 60 non-amblyopic eyes, uncorrected visual acuity was > or = 20/20 in 47 (78%) eyes. Thirty-three (47%) eyes gained 1 to 2 lines of Snellen decimal equivalent best spectacle-corrected visual acuity, 30 (43%) eyes showed no change, and 7 (10%) eyes lost 1 line. Eight (11%) eyes at 12 to 24 months had grade +/- 1 of paracentral corneal haze and 57 (81%) had no haze. At 12 months (n = 70), the safety index was 1.06 with an efficacy index of 0.95. Analysis of higher order wavefront aberrations showed no significant changes in root-mean-square values post-operatively, except for a significant reduction of fourth order spherical aberration (P < .05). CONCLUSIONS: Laser epithelial keratomileusis for hyperopia up to +5.00 D using a 7.0-mm optical zone with the Schwind ESIRIS laser provides excellent refractive and visual outcomes with minimal complications. In eyes followed for 24 months, the refractive correction remained stable after 6 months.     

Laser in situ keratomileusis for hyperopia and hyperopic astigmatism using the Meditec MEL 70 spot scanner

PURPOSE: To evaluate safety, predictability, efficacy, and stability of laser in situ keratomileusis (LASIK) for spherical hyperopia and hyperopia with astigmatism. METHODS: In this retrospective study we analyzed the results of 23 eyes of 23 patients who had LASIK for spherical hyperopia (preoperative cylinder < or = 0.75 D) and 44 eyes of 44 patients who had LASIK for hyperopia with astigmatism; (Bausch & Lomb Hansatome microkeratome with a 180-microm plate and a suction ring for a 9.5-mm flap diameter; Asclepion-Meditec MEL 70 G-scan flying spot laser with a 1.8-mm Gaussian beam). RESULTS: In Group 1 (spherical hyperopia), mean preoperative spherical equivalent refraction was +4.88 +/- 2.13 D (range +2.13 to +9.63 D); in Group 2 (hyperopic astigmatism), +4.33 +/- 2.15 D (range +0.50 to +9.50 D). One year after LASIK, mean spherical equivalent refraction was +0.30 +/- 0.90 D (range -0.75 to +2.50 D) in Group 1 and +0.29 +/- 1.27 D (range -3.25 to +3.25 D) in Group 2. In Group 1, 78%, and in Group 2, 42% were within +/- 0.50 D. In Group 1, no eyes lost two or more lines, and one eye (6%) lost one line of best spectacle-corrected visual acuity at 1 year. In Group 2, one eye (4%) lost one line and one eye (4%) lost more than two lines at 1 year. Uncorrected visual acuity of 20/40 or better was achieved in 83% (Group 1) vs. 62% (Group 2) at 1 year; these values improved to 100% vs. 71% for corrections up to +6.00 D. CONCLUSIONS: LASIK with the Meditec MEL 70 G-Scan flying spot laser seemed to be safe and effective for hyperopia and hyperopia with astigmatism for corrections up to +6.00 D. Large flap diameters are necessary to avoid epithelial ingrowth.     

Hyperopic laser in situ keratomileusis: primary and secondary treatments are safe and effective

PURPOSE: To retrospectively analyze the safety and efficacy of hyperopic laser in situ keratomileusis (LASIK) treatment of eyes with primary hyperopia and consecutive hyperopia after initial myopic treatment. METHODS: Thirty-two eyes of 19 patients with primary hyperopia (group 1) and 37 eyes of 26 patients with consecutive hyperopia after initial myopic LASIK overcorrection (group 2) that had LASIK for hyperopia with the Hansatome microkeratome and VISX S2 Smoothscan excimer laser with 6 months' follow-up after surgery were analyzed. Uncorrected visual acuity, best spectacle-corrected visual acuity, fogged manifest refraction, and corneal topography with corneal irregularity measurement (CIM) were evaluated 1 month, 3 months, and 6 months after surgery. RESULTS: In group 1, the mean preoperative cycloplegic spherical equivalent was +4.0 +/- 4.5 diopters (D) (range, +1.5 to + 8.75 D) and the 6-month postoperative cycloplegic spherical equivalent was +0.26 +/- 1.74 D (range, -3.00 to +2.75 D). Fifty-three percent of eyes (n= 17) in group 1 were within 1 D of emmetropia. Sixty-six percent of eyes (n= 21) had uncorrected visual acuity of at least 20/40. Three eyes (9%) lost two lines of best spectacle-corrected visual acuity. Changes in uncorrected visual acuity, best spectacle-corrected visual acuity, spherical equivalent, and the CIM topographic index 6 months after surgery were statistically significant compared with the preoperative values. In group 2, the mean preoperative cycloplegic spherical equivalent was +1.58 +/- 0.35 D (range, +0.125 to +2.75 D), and the mean postoperative cycloplegic spherical equivalent was -0.48 +/- 0.46 (range, -2.75 to +0.38 D). Eighty-six percent of eyes (n= 32) were within 1 D of emmetropia. Eighty-four percent of eyes (n= 31) in group 2 had uncorrected visual acuity of at least 20/40. One eye (2.7%) lost two lines of best spectacle-corrected visual acuity. Complications included an epithelial nest that resolved 3 months after surgery in one eye in group 2. CONCLUSIONS: LASIK is a relatively safe treatment of primary hyperopia and hyperopia resulting from overcorrection after initial LASIK treatment of myopia (consecutive hyperopia). Patients with high hyperopia (>5 D) are at risk for loss of two lines of best spectacle-corrected visual acuity. A reduction in the level of attempted correction appears to be necessary in the treatment of consecutive hyperopia.     

Long-term follow-up of hyperopic laser in situ keratomileusis correction using the Star S2 excimer laser

PURPOSE: To prospectively evaluate the safety, efficacy, predictability, and long-term stability of hyperopic laser in situ keratomileusis (LASIK) using the Star S2 excimer laser (Visx). SETTING: Department of Ophthalmology, Stanford University School of Medicine, Stanford, California, USA. METHODS: This study evaluated 41 eyes of 27 patients who had LASIK for the correction of spherical hyperopia. Patients were divided into 3 groups based on preoperative cycloplegic refraction: low hyperopia (less than +2.00 diopters [D]), medium hyperopia (+2.00 to +4.00 D), and high hyperopia (more than +4.00 D). RESULTS: In all eyes, the mean preoperative spherical equivalent (SE) was +2.53 D (range +0.75 to +5.25 D) and the mean attempted SE was +2.58 D (range +0.75 to +5.25 D). At the last visit (mean 5.29 years), the mean SE was +0.44 D +/- 0.69 (SD) in the low hyperopia group, +0.58 +/- 0.56 D in the medium hyperopia group, and +0.59 +/- 1.18 D in the high hyperopia group. The percentage of eyes within +/-1.00 D of emmetropia was 82.4%, 75.0%, and 66.7%, respectively (68.9% overall). The uncorrected visual acuity was 20/40 or better in 100% of eyes in the low hyperopia group, 91.7% in the medium hyperopia group, and 66.7% in the high hyperopia group (87.8% overall). The hyperopic shift between 1 year and the last visit was +0.18 D, +0.30 D, and +0.55 D, respectively (+0.40 D overall; range -1.25 to +2.63 D). CONCLUSIONS: Hyperopic LASIK using the Star S2 excimer laser was safe, effective, and predictable for hyperopia up to +4.10 D (mean of high group). A mild regression of the refractive effect was seen over the 5-year follow-up.     

Photorefractive keratectomy to correct hyperopic shift after radial keratotomy

To evaluate the safety, efficacy, and predictability of photorefractive keratectomy (PRK) to correct post-radial-keratotomy (RK) hyperopic shift.University of Sherbrooke, Sherbrooke, Québec, Canada.This retrospective nonconsecutive case series comprised 53 eyes of 53 patients who had PRK to correct hyperopic shift after RK. Both RK and PRK were performed by the same surgeon at the same clinic from 1993 to 2001.The mean time after RK was 57 months (range 24 to 84 months). The mean follow-up after hyperopic PRK (HPRK) was 10 months (range 3 to 33 months). The mean hyperopic shift 1 month post-RK to HPRK was +1.6 diopters (D) +/- 1.0 (SD) (range +0.25 to +4.125 D). The mean pre-HPRK spherical equivalent (SE) was +2.15 +/- 0.80 D (range +1.00 to +4.125 D) and the mean post-HPRK SE, -0.10 +/- 0.80 D (range -2.00 to +2.125 D). At the last examination, 47 eyes (88.7%) had a refractive error within +/-1.0 D of emmetropia and 38 eyes (71.7%) had an uncorrected visual acuity of 20/25 or better. Two eyes lost 1 Snellen line of best corrected visual acuity. No significant haze or complications developed in any eye.Hyperopic PRK with a conservative technique (large optical zone and small ablation thickness) can be used successfully to correct RK-induced hyperopia in patients with small to moderate refractive errors. It appeared to be effective, predictable, and safe.     

Myopic and hyperopic laser in situ keratomileusis retreatments: indications, techniques, limitations, and results

PURPOSE: To assess the efficacy of myopic and hyperopic laser in situ keratomileusis (LASIK) retreatment procedures. SETTING: Mater Private Hospital, Dublin, Ireland. METHODS: Retreatment was defined as either lifting the previously created flap or when this was not possible, cutting a new flap. Fifty-six patients were retreated, 17 with hyperopia (Group 1) and 39 with myopia (Group 2). The mean preoperative spherical equivalent in Group 1 was +3.79 diopters (D) +/- 1.53 (SD) (range +1.75 to +8.12 D) and in Group 2, -5.46 +/- 2.87 D (range -0.38 to -15.25 D). RESULTS: The indications for retreatment were undercorrection, decentration, epithelial ingrowth, and central island. Postoperatively, the mean spherical equivalents in Groups 1 and 2 were +1.11 +/- 2.02 D (range -1.75 to +5.50 D) and -1.02 +/- 2.20 D (range +4.75 to -9.00 D), respectively. In Group 1, the uncorrected visual acuity (UCVA) was 6/12 or better in 5.8% preoperatively and in 35% postoperatively. In Group 2, the UCVA was 6/12 or better in 5.1% preoperatively and in 59.0% postoperatively. Although 29% of the hyperopic eyes and 8% of the myopic eyes lost 1 Snellen line of best corrected visual acuity (BCVA), there was an improvement (of 1 or more lines) in BCVA in 12% and 49%, respectively. In cases that were decentered preoperatively, the postoperative optical zone ablation centration was better in 85.7% of Group 1 eyes and 61.5% of Group 2 eyes. Corneal complications following retreatment included peripheral scarring, epithelial ingrowth, Bowman's folds, and keratectasia. CONCLUSIONS: Both myopic and hyperopic retreatments resulted in a stable refractive outcome. Myopic retreatments were superior to hyperopic retreatments in both efficacy and safety.     

Laser in situ keratomileusis for spherical hyperopia and hyperopic astigmatism using the NIDEK EC-5000 excimer laser

PURPOSE: To assess the efficacy, predictability, and safety of LASIK for the surgical correction of low to moderate hyperopia and hyperopic astigmatism using the NIDEK EC-5000 excimer laser. METHODS: In a multicenter United States Food and Drug Administration (FDA) regulated study of LASIK, 7 centers enrolled 293 eyes with manifest refraction sphere that ranged from +0.50 to +6.00 diopters (D) with or without astigmatism up to 3.00 D. The intended outcome was plano in all eyes. Patients were treated bilaterally. One year postoperative outcomes are reported. RESULTS: The mean spherical equivalent refraction (MRSE) for all eyes changed from +2.61 +/- 1.19 D (range: +0.50 to +6.63 D) preoperatively to +0.35 +/- 0.54 D (range: -1.63 to +2.00 D) 1 year postoperatively. Overall, 61% (170/279) of eyes achieved distance uncorrected visual acuity (UCVA) of 20/20 or better, 82% (228/279) of eyes saw 20/25 or better, and 99% (277/279) of eyes saw 20/40 or better. Refractive accuracy was demonstrated as 63.1% (176/279) of eyes achieved a MRSE within +/- 0.50 D and 90.3% (252/279) of eyes within +/- 1.00 D. Less than 2% (4/279) of eyes lost 2 lines of distance best spectacle-corrected visual acuity. Stability of refraction was demonstrated by 6 months, with a mean hyperopic shift of < 0.03 D from 3 to 6 months. CONCLUSIONS: The NIDEK EC-5000 corrected hyperopia and hyperopic astigmatism with UCVA, refractive accuracy, 1-year stability, and safety that surpassed all FDA criteria.     

Two-year follow-up of laser in situ keratomileusis for hyperopia

PURPOSE: To evaluate excimer laser in situ keratomileusis (LASIK) for hyperopia and its predictability. METHODS: We performed a retrospective study of 100 eyes that had LASIK for hyperopia to assess predictability and long-term stability of refractive results. The Chiron Automated Corneal Shaper was used to create the flap and the Keracor 117CT Chiron-Technolas excimer laser with the plano-scan program was used to ablate all corneas. RESULTS: Mean baseline spherical equivalent manifest refraction was +4.50 +/- 1.73 D (range, +1.25 to +8.50 D). Six months after LASIK, mean manifest spherical equivalent refraction was +0.72 +/- 1.87 D (range, -1.75 to +2.50 D), at 1 year, +0.88 +/- 1.73 D (range, -1.25 to +2.50 D), and at 2 years, +0.85 +/- 1.74 D (range, -0.50 to +2.75 D). Two years after LASIK, 45 eyes (74%) were within +/-1.00 D of intended correction and within +/-1.00 D of emmetropia. Uncorrected visual acuity was 20/40 or better in 50 eyes (82%) at 2 years; 29 eyes (37%) saw 20/20 or better. Undercorrection occurred more frequently in eyes with preoperative keratometric power of more than 45.00 D, when ablation zones less than 6 mm were used and when higher amounts of hyperopic correction were required. CONCLUSION: LASIK with the Keracor 117CT excimer laser appears to be an effective and safe procedure to correct hyperopia. Preoperative keratometric power, amount of hyperopia, and ablation zone diameter affect the efficacy and long-term stability of the procedure.     

Laser in situ keratomileusis for the correction of hyperopia from +1.25 to +5.00 diopters with the Technolas Keracor 117C laser

PURPOSE: To assess the efficacy, predictability, stability, and safety of laser in situ keratomileusis (LASIK) in patients with hyperopia and to evaluate the visual and refractive results of the procedure. METHODS: LASIK was performed on 85 eyes of 53 patients for correction of hyperopia, with a preoperative mean manifest spherical equivalent refraction of +3.31 +/- 0.69 D (range, +1.25 to +5.00 D) and mean refractive astigmatism of +0.91 +/- 1.06 D (range, 0 to +3.00 D). The Carriazo-Barraquer (Moria) manual microkeratome was used to create the corneal flap, and laser ablation was performed using the Technolas Keracor 117C excimer laser with an ablation zone diameter of 6.0 mm and a transition zone diameter to 9.0 mm. Follow-up was 12 months for all patients. RESULTS: Refraction was stable by 3 months after surgery. At 1 year after LASIK, the mean manifest spherical equivalent refraction was +0.43 +/- 0.57 D (range, -1.25 to +2.00 D) and refractive astigmatism was reduced to a mean of 0.36 +/- 0.30 D (range, 0 to 1.00 D). Fifty-two eyes (61.2%) had a manifest spherical equivalent refraction within +/- 0.50 D of emmetropia, and 76 eyes (89.4%) were within +/- 1.00 D. Uncorrected visual acuity was 20/20 in 21 eyes (24.7%) and 20/40 or better in 79 eyes (92.9%). Spectacle-corrected visual acuity was reduced by two lines in one eye (1.2%) and improved by two lines in five eyes (5.9%). There were no significant complications. CONCLUSION: LASIK was an effective, safe, and predictable procedure for the correction of hyperopia up to +5.00 D and hyperopic astigmatism up to +3.00 D with the Technolas Keracor 117C excimer laser. The large size of the corneal flap obtained by the Carriazo-Barraquer (Moria) manual microkeratome facilitated laser ablation entirely in the exposed corneal stromal bed.